



## Disclosures

### Personal Commercial (6)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
<i>Self</i>			
AbbVie, Inc.	Research/Research Grants ‡ VIP-extension adalimumab trial	Significant (>= \$5,000)	Other
Abcentra	Consultant Fees/Honoraria	Significant (>= \$5,000)	
Celgene Corporation	Research/Research Grants ‡ VIP-Apremilast	Significant (>= \$5,000)	Other
Janssen Pharmaceuticals, Inc	Research/Research Grants ‡ VIP-ustekinumab	Significant (>= \$5,000)	Other
NIH	Research/Research Grants	Significant (>= \$5,000)	
Novartis Corporation	Research/Research Grants ‡ VIP-Secukinumab	Significant (>= \$5,000)	Other

### Additional Personal Commercial Disclosures for Education Activities (1)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
<i>Self</i>			
Caristo	Consultant Fees/Honoraria	Significant (>= \$5,000)	

### Personal Organizational or Other Non-Commercial (1)

Non-Commercial Entity Name	Relationship Category	Compensation Level	Topic Area(s)
<i>Self</i>			
National Institutes of Health	Research/Research Grants ‡ PACI Cohort Study	Significant (>= \$5,000)	Noninvasive Imaging

### Clinical Trial Enroller (0)

No disclosures on record

### Institutional Financial Decision-Making Role (0)

No disclosures on record

### Expert Witness Testimony (0)

No disclosures on record

‡ Commercial Funding Source | ‡ Trial Name

## Agreement

### Certified Education Attestation | Signed on 10/12/2023

URL for full agreement: <http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement>

### Confidentiality, Disclosure and Assignment Agreement | Signed on 10/12/2023

URL for full agreement: <http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement>

### Embargo | Signed on 10/12/2023

URL for full agreement: <http://disclosures.acc.org/Public/Definition/EmbargoAgreement>

### On-Going Obligation Agreement | Signed on 10/12/2023

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.